Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $742.38 (market cap $76.14B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.05 (market cap $3.80B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 20× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| REGN | VNQI | |
|---|---|---|
Market Cap | $76.14B | $3.80B |
Volume | 500,239 | 277,049 |
Sector | Health | — |
52-Week High | $852.03 | $50.76 |
52-Week Low | $557.73 | $41.81 |
Typical Hold Time | 107 Days | 95 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
VNQI trades at $42.06, up 0.6% with a bearish technical signal from moving averages. The ETF focuses on international real estate across 30+ countries, offering diversification but facing recent price pressure below key moving averages. Short interest declined 45.9% in September (Defense World, 2026-10-02), potentially indicating reduced bearish sentiment despite the technical downtrend.
The outlook remains cautious given bearish technicals and international real estate exposure risks. Competitive advantages include lower expense ratios (0.12%) and higher dividend yields versus peers. Key risks involve global economic sensitivity and currency fluctuations affecting international holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
